Asghar Marzban

Asghar Marzban


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Early Human Development
Verified
Journal Article
Closed access
FSFarin Soleimani
Farin Soleimani
RBReza Shervin Badv
Reza Shervin Badv
AMAmin Momayezi
Amin Momayezi
ABAkbar Biglarian
Akbar Biglarian
AMAsghar Marzban
Asghar Marzban

25 October 2016 in Behavioural Neurology
Verified
Journal Article
Open access
PDF file
BPBagher Pourheydar
Bagher Pourheydar
SASara Sara Soleimani Asl
Sara Sara Soleimani Asl
Mostafa AzimzadehMostafa Azimzadeh
Mostafa Azimzadeh
AMAdel Rezaei Moghadam
Adel Rezaei Moghadam
AMAsghar Marzban
Asghar Marzban
MMmehdi mehdizadeh
mehdi mehdizadeh
Cell therapy is the most advanced treatment of the cerebral ischemia, nowadays. Herein, we discuss the neuroprotective effects of bone marrow mesenchymal stem cells (BMSCs) on rat hippocampal cells following intravenous injection of these cells in an ischemia-reperfusion model. Adult male Wistar rats were divided into 5 groups: control, sham (surgery without blockage of common carotid arteries), ischemia (common carotid arteries were blocked for 30 min prior to reperfusion), vehicle (7 days after ischemia PBS was injected via the tail vein), and treatment (injections of BMSC into the tail veins 7 days after ischemia). We performed neuromuscular and vestibulomotor function tests to assess behavioral function and, finally, brains were subjected to hematoxylin and eosin (H&E), anti-Brdu immunohistochemistry, and TUNEL staining. The ischemia group had severe apoptosis. The group treated with BMSCs had a lower mortality rate and also had significant improvement in functional recovery (P<0.001). Ischemia-reperfusion for 30 min causes damage and extensive neuronal death in the hippocampus, especially in CA1 and CA3 regions, leading to several functional and neurological deficits. In conclusion, intravenous injection of BMSCs can significantly decrease the number of apoptotic neurons and significantly improve functional recovery, which may be a beneficial treatment method for ischemic injuries.

20 April 2024 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
AMAsghar Marzban
Asghar Marzban
SMSamira Mokhtari
Samira Mokhtari
PTPouria Tavakkolian
Pouria Tavakkolian
RMReza Mansouri
Reza Mansouri
NJNahid Jafari
Nahid Jafari
AMAzam Maleki
Azam Maleki
Background: Respiratory distress syndrome (RDS) is one of the most important and common disorders among premature infants. Objective: This study aimed to compare the effect of the combination of surfactant and budesonide with surfactant alone on Bronchopulmonary dysplasia (BPD) and mortality rate among premature infants with RDS. Method: An outcome assessor-blind randomized clinical trial was conducted on 134 premature infants with RDS who were born in Ayatollah Mousavi Hospital, Zanjan, Iran in 2021. The covariate adaptive randomization method was utilized to allocate participants into two groups (surfactant alone and a combination of surfactant and budesonide). The primary outcomes were BPD and Mortality rate from admission to hospital discharge. The data in this study were analyzed using SPSS software version 18. Results: Overall the comparison of mortality rate and BPD between the two groups did not show a significant difference(p > 0.05). The subgroup results showed that administering surfactant with budesonide to infants under 30 weeks of age significantly reduced the number of deaths compared to using surfactant alone (5 vs. 17). Similar positive effects were observed for the occurrence of Pulmonary Hemorrhage, the need for a second dose of surfactant, oxygen index, mean blood pressure and mean arterial pressure (MAP) in infants under 34 weeks of age compared to more than 34 weeks (p < 0.05). Conclusion: These findings suggest that the combination therapy of surfactant and budesonide may be beneficial, particularly in preterm infants with less than 34 weeks gestational age and 1500 birth weight. However, further studies with larger sample sizes and longer follow-up periods are needed to confirm these results and assess long-term outcomes. Trial registration: The study was registered at the Iranian Registry of Clinical Trials website under the code IRCT20201222049802N1. https://en.irct.ir/user/trial/48117/view. Registration date: 28/02/2021. Public repository: Data set: This research data set link is displayed on the Zanjan-Iran Medical Sciences website: https://repository.zums.ac.ir/cgi/users/login? target=https%3 A%2 F/repository.zums.ac.ir/id/eprint.

Verified
Journal Article
Open access
PDF file
MMmehdi mehdizadeh
mehdi mehdizadeh
NANiloufar Ashtari
Niloufar Ashtari
XJXiaodan Jiao
Xiaodan Jiao
MRMaryam Rahimi-Balaei
Maryam Rahimi-Balaei
AMAsghar Marzban
Asghar Marzban
Hassan MarzbanHassan Marzban
Hassan Marzban
A spontaneous mutation in the lysosomal acid phosphatase (Acp2) enzyme (nax: naked–ataxia) in experimental mice results in delayed hair appearance and severe cytoarchitectural impairments of the cerebellum, such as a Purkinje cell (PC) migration defect. In our previous investigation, our team showed that Acp2 expression plans a significant role in cerebellar development. On the other hand, the dopaminergic system is also a player in central nervous system (CNS) development, including cerebellar structure and function. In the current investigation, we have explored how Acp2 can be involved in the regulation of the dopaminergic pathway in the cerebellum via the regulation of dopamine receptor expression and patterning. We provided evidence about the distribution of different dopamine receptors in the developing cerebellum by comparing the expression of dopamine receptors on postnatal days (P) 5 and 17 between nax mice and wild–type (wt) littermates. To this aim, immunohistochemistry and Western blot analysis were conducted using five antibodies against dopamine receptors (DRD1, –2, –3, –4, and –5) accompanied by RNAseq data. Our results revealed that DRD1, –3, and –4 gene expressions significantly increased in nax cerebella but not in wt, while gene expressions of all 5 receptors were evident in PCs of both wt and nax cerebella. DRD3 was strongly expressed in the PCs’ somata and cerebellar nuclei neurons at P17 in nax mice, which was comparable to the expression levels in the cerebella of wt littermates. In addition, DRD3 was expressed in scattered cells in a granular layer reminiscent of Golgi cells and was observed in the wt cerebella but not in nax mice. DRD4 was expressed in a subset of PCs and appeared to align with the unique parasagittal stripes pattern. This study contributes to our understanding of alterations in the expression pattern of DRDs in the cerebellum of nax mice in comparison to their wt littermates, and it highlights the role of Acp2 in regulating the dopaminergic system.

3 February 2011
Verified
Journal Article
Closed access
AMAsghar Marzban
Asghar Marzban
HSHadi Samaee
Hadi Samaee
NMNoredien Mosavinasab
Noredien Mosavinasab

1 May 2008
Verified
Journal Article
Closed access
HSHadi Samaee
Hadi Samaee
PSParvaneh Sadeghi-Moghadam
Parvaneh Sadeghi-Moghadam
AAAbdollah Arab-Hosseini
Abdollah Arab-Hosseini
MAMohammad Reza Aramesh
Mohammad Reza Aramesh
AMAsghar Marzban
Asghar Marzban